This site is intended for healthcare professionals

News

Phase II DESTINYLung01 trial positive for Enhertu/Enhurtu in HER2 mutant NSCLC.- Daiichi Sankyo and AstraZeneca.

Read time: 1 mins

Last updated:2nd Jun 2020

Published:2nd Jun 2020

Condition: Non Small Cell Lung Cancer

Type: drug

Register free for full access to medthority.com

Click here to register now